Pathway Biopharma

Pathway Biopharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of high-quality biosimilars for global markets. Headquartered in South San Francisco with significant R&D and manufacturing operations in India, the company targets major therapeutic areas including oncology, immunology, and ophthalmology. Its pipeline features biosimilar candidates for blockbuster biologics such as bevacizumab, trastuzumab, and rituximab, with its lead program having reached Phase 3 clinical trials. The company leverages a cost-effective development model and a team of industry veterans to increase the affordability and accessibility of complex biologic treatments. Pathway Biopharma aims to bridge the gap between expensive reference biologics and patient needs through rigorous scientific standards and streamlined regulatory strategies.